Rallidae Therapeutics is developing vasopressin V1aR partial agonists as next gen pressors to prevent renal injury caused by vasodilatory hypotension in cirrhotic liver disease, vasodilatory shock, and CKD. Safety and efficacy of the Rallidae approach is clinically validated, with a clear path to a once weekly SC NCE and an IV clinical asset, transforming care and saving lives in large markets with few therapeutic solutions today.

We are talking with partners and investors to advance discovery and development of V1aR partial agonists, preventing renal injury and other consequences of vasodilatory hypotension.